AOTMiT: Transparency Council, among others will evaluate drugs for lung cancer and AS

The agenda includes:
Preparation of a position on the assessment of the legitimacy of qualifying health care services "Transcranial magnetic stimulation (TMS) - rTMS and iTBS protocols in the treatment of treatment-resistant depression" as a guaranteed service.
Preparation of positions on drug evaluation:
• Libtayo (cemiplimabum) under the drug program B.6. "Treatment of non-small cell or small cell lung cancer (ICD -10 C 34)",
• Xeljanz (tofacitinib) under the drug program B.36. “Treatment of patients with active ankylosing spondylitis (AS) (ICD-10:M45).
Preparation of positions on the legitimacy of granting consent for the reimbursement of the medicinal product Raxone (idebenone) in the following indications:
• Leber's hereditary optic neuropathy;
• Leber's hereditary optic neuropathy - continuation of treatment in which the patient has benefited.
Preparation of opinions on draft health policy programs of local government units:
• "Reproductive health support program dedicated to the residents of Radom",
• "Health Policy Program for preserving fertility in oncological patients in the Lower Silesian Voivodeship".

Source: AOTMiT